Pharmaceuticals

New data on ATX-295 reveals a potent attack on unstable tumors, guided by an AI biomarker that could change how we select patients for treatment.

Nested Therapeutics' NST-628 reports a 38% response rate in advanced melanoma, offering new hope with a novel, brain-penetrating cancer-fighting agent.

Interim study results suggest a common food product may significantly enhance the effectiveness of modern cancer treatments, heralding a new era of care.

A new partnership between Wilcrest Pharma and healthcare giant Premier, Inc. aims to streamline hazardous drug compounding for thousands of U.S. hospitals.

With global regulatory approvals secured, Gilead extends its tender offer for Arcellx, moving closer to acquiring a potential best-in-class CAR T therapy.

A new report reveals the Nordic life science sector isn't lacking female talent; it's failing to convert it into leadership, threatening innovation.

Early Phase 2 data shows invikafusp alfa plus TRODELVY® yields complete responses in heavily pretreated breast cancer, offering a potential new lifeline.

Biotech veteran Habib Dable, who led Acceleron to an $11.5B Merck sale, joins Tyra Biosciences' board, signaling a major push toward commercialization.

Byondis presents two novel ADC platforms at AACR 2026, aiming to solve drug resistance and offer hope for patients unresponsive to immunotherapy.

A European consortium has won €1.3M to develop a precision therapy for chronic urticaria, offering new hope for millions with uncontrolled symptoms.

With $36M secured, Orthogon Therapeutics is advancing a first-in-class oral drug for BK virus, offering a new lifeline for transplant patients.

Las Vegas trial lawyer Robert Eglet's induction into the Trial Lawyer Hall of Fame signals a new era for the city and a legacy of corporate accountability.

New data reveals Mapi Pharma's long-acting GA Depot stabilizes disability in both relapsing and progressive MS, poised for a 2027 European launch.

Patients, doctors, and researchers unite for a grueling ride across Iceland, raising funds and hope for a future free from multiple myeloma.

A new oral drug candidate for lupus and RA emerges as Totus Medicines uses its AI platform to rapidly develop a first-in-class inhibitor for the elusive IRF5 protein.

Biopharma veteran Glenn Gormley joins Aktis's board, bringing deep ADC expertise to guide the company's next-gen radiopharmaceutical pipeline.

A novel drug for a debilitating stomach disorder is set for a major reveal, offering hope to millions with limited and often risky treatment options.

A new survey shows nearly half of employers are considering international drug sourcing, a legally murky strategy, as cost control dethrones talent retention.

GC Biopharma's new data on ALYGLO's purity profile could set a new standard for IVIG therapies, impacting patient safety in a rapidly growing market.

A new partnership combines live biopsy analysis with agentic AI, seeking to predict immunotherapy response and solve why only 1 in 5 patients benefit.